Somatic Stem Cell Isolation and Dendritic Cell Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The use of human embryonic stem cells for treating degenerative or inherited diseases is hindered by ethical considerations, necessitating the development of non-embryonic stem cell alternatives that can effectively differentiate and regenerate tissues.

Innovation Solution

A method involving the isolation and differentiation of somatic stem cells from bodily fluids, using EDTA or heparin to separate a population of cells 0.3-6.0 micrometers in size, which are then differentiated into dendritic cells or directly administered to treat various degenerative disorders, including cancer, liver damage, brain tissue damage, and muscle injuries, using growth factors and cytokines like GCSF, SCF, EGF, PDGF, bFGF, and IL-3.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If human embryonic stem cells are used to treat degenerative or inherited diseases, then therapeutic effectiveness is improved, but ethical considerations create barriers to their use

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidethical considerations

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses induced pluripotent stem cells (iPSCs) as an intermediary between embryonic stem cells and somatic cells. iPSCs provide the therapeutic benefits of embryonic stem cells while avoiding the ethical issues of embryo destruction, serving as a mediator that resolves the contradiction between effectiveness and ethics

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the source parameter of stem cells from embryonic to induced pluripotent or somatic origin. This parameter change maintains the pluripotent or multipotent characteristics necessary for therapy while eliminating the ethical barriers associated with embryonic stem cells

Inventive Principle:

Principle #35Parameter changes

2Reliability

If somatic stem cells are isolated and differentiated into dendritic cells for cancer treatment, then immunotherapy effectiveness is improved, but the complexity of the differentiation process increases

Engineering Contradiction:

Improveimmunotherapy effectivenessVSAvoiddifferentiation process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary actions by pre-differentiating somatic stem cells into dendritic cells ex vivo before administration. Growth factors and cytokines are added in advance to guide differentiation, simplifying the in vivo process and improving therapeutic effectiveness

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses dynamic control of differentiation conditions by adjusting growth factor concentrations and exposure times. This dynamic approach allows optimization of the differentiation process to achieve high purity dendritic cells while managing process complexity

Inventive Principle:

Principle #15Dynamics

3Ease of operation

If small somatic stem cells (0.3-6.0 micrometers) are isolated from bodily fluids, then ease of isolation is improved, but the low concentration of target cells makes identification difficult

Engineering Contradiction:

Improveease of isolationVSAvoidtarget cell identification difficulty

Core Design Contradiction:

Ease of operationVSDifficulty of detecting and measuring

Solution Approach 1:

The patent uses fluorescent markers and staining techniques to change the detectable properties of target cells. This allows visualization and identification of rare somatic stem cells in bodily fluids through their fluorescent signal, overcoming the difficulty of detecting low-concentration target cells

Inventive Principle:

Principle #32Color changes

Solution Approach 2:

The patent replaces mechanical isolation methods with magnetic-activated cell sorting (MACS) or flow cytometry based on surface markers. This substitution improves ease of isolation by automating the process and enhancing the ability to detect and sort rare cells based on their magnetic or fluorescent properties

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the effective treatment of multiple degenerative disorders by utilizing autologous somatic stem cells that can differentiate into various cell types, minimizing host rejection and ethical concerns, and promoting tissue repair and regeneration.

Implementation Method 1

incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer

Methodology Applied

Scientific EffectDensity gradient centrifugation: Centrifugal Separation

Data Source

PatentUS8986679B2Somatic stem cells

Publication Date: 2015.03.24 STEMBIOS TECHNOLOGIES INC

AI summary

A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof.